|
Gene: ANO9 |
Gene summary for ANO9 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ANO9 | Gene ID | 338440 |
Gene name | anoctamin 9 | |
Gene Alias | PIG5 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A1A5B4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
338440 | ANO9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.40e-02 | -8.79e-02 | 0.0155 |
338440 | ANO9 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.29e-09 | 5.61e-01 | -0.1808 |
338440 | ANO9 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.63e-04 | 2.58e-01 | -0.1954 |
338440 | ANO9 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.17e-03 | 4.21e-01 | -0.1207 |
338440 | ANO9 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.55e-05 | 4.26e-01 | -0.059 |
338440 | ANO9 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.85e-05 | 4.10e-01 | 0.3859 |
338440 | ANO9 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.60e-03 | 3.44e-01 | 0.3005 |
338440 | ANO9 | A015-C-203 | Human | Colorectum | FAP | 3.67e-14 | 3.06e-01 | -0.1294 |
338440 | ANO9 | A002-C-201 | Human | Colorectum | FAP | 1.57e-04 | 2.78e-01 | 0.0324 |
338440 | ANO9 | A001-C-108 | Human | Colorectum | FAP | 1.84e-03 | 2.07e-02 | -0.0272 |
338440 | ANO9 | A002-C-205 | Human | Colorectum | FAP | 8.11e-06 | 1.41e-01 | -0.1236 |
338440 | ANO9 | A015-C-006 | Human | Colorectum | FAP | 4.76e-13 | 5.19e-01 | -0.0994 |
338440 | ANO9 | A015-C-106 | Human | Colorectum | FAP | 8.71e-04 | 1.70e-01 | -0.0511 |
338440 | ANO9 | A002-C-114 | Human | Colorectum | FAP | 1.05e-04 | 1.11e-01 | -0.1561 |
338440 | ANO9 | A015-C-104 | Human | Colorectum | FAP | 1.87e-20 | 3.66e-01 | -0.1899 |
338440 | ANO9 | A015-C-202 | Human | Colorectum | FAP | 7.49e-03 | 3.00e-01 | -0.0849 |
338440 | ANO9 | A001-C-014 | Human | Colorectum | FAP | 1.12e-02 | -8.91e-02 | 0.0135 |
338440 | ANO9 | A002-C-016 | Human | Colorectum | FAP | 2.82e-06 | -2.08e-01 | 0.0521 |
338440 | ANO9 | A015-C-002 | Human | Colorectum | FAP | 2.13e-02 | 1.66e-01 | -0.0763 |
338440 | ANO9 | A002-C-116 | Human | Colorectum | FAP | 8.50e-11 | -2.35e-01 | -0.0452 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
GO:0051051 | Colorectum | SER | negative regulation of transport | 98/2897 | 470/18723 | 1.01e-03 | 1.19e-02 | 98 |
GO:0007009 | Colorectum | SER | plasma membrane organization | 36/2897 | 142/18723 | 1.50e-03 | 1.62e-02 | 36 |
GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
GO:0022898 | Colorectum | MSS | regulation of transmembrane transporter activity | 70/3467 | 278/18723 | 3.36e-03 | 2.54e-02 | 70 |
GO:00510511 | Colorectum | MSS | negative regulation of transport | 110/3467 | 470/18723 | 4.20e-03 | 3.04e-02 | 110 |
GO:0032412 | Colorectum | MSS | regulation of ion transmembrane transporter activity | 66/3467 | 267/18723 | 6.72e-03 | 4.38e-02 | 66 |
GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
GO:00228981 | Colorectum | FAP | regulation of transmembrane transporter activity | 62/2622 | 278/18723 | 1.09e-04 | 1.80e-03 | 62 |
GO:00324121 | Colorectum | FAP | regulation of ion transmembrane transporter activity | 60/2622 | 267/18723 | 1.12e-04 | 1.84e-03 | 60 |
GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
GO:00510512 | Colorectum | FAP | negative regulation of transport | 91/2622 | 470/18723 | 7.09e-04 | 7.64e-03 | 91 |
GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
GO:00156981 | Colorectum | FAP | inorganic anion transport | 38/2622 | 180/18723 | 5.73e-03 | 3.67e-02 | 38 |
GO:0015914 | Colorectum | FAP | phospholipid transport | 23/2622 | 96/18723 | 6.09e-03 | 3.82e-02 | 23 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANO9 | SNV | Missense_Mutation | rs778954042 | c.643N>A | p.Gly215Arg | p.G215R | A1A5B4 | protein_coding | deleterious(0.03) | possibly_damaging(0.636) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | rs140961109 | c.985N>T | p.Arg329Cys | p.R329C | A1A5B4 | protein_coding | deleterious(0.01) | probably_damaging(0.944) | TCGA-AX-A3GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ANO9 | SNV | Missense_Mutation | c.1928C>T | p.Thr643Ile | p.T643I | A1A5B4 | protein_coding | tolerated(0.07) | possibly_damaging(0.465) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
ANO9 | SNV | Missense_Mutation | rs765320102 | c.1555N>A | p.Glu519Lys | p.E519K | A1A5B4 | protein_coding | tolerated(0.89) | possibly_damaging(0.559) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | novel | c.104N>G | p.Asp35Gly | p.D35G | A1A5B4 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | novel | c.1049N>C | p.Val350Ala | p.V350A | A1A5B4 | protein_coding | tolerated(1) | benign(0.006) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | novel | c.219N>T | p.Gln73His | p.Q73H | A1A5B4 | protein_coding | tolerated(0.05) | benign(0.047) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | novel | c.1318G>A | p.Ala440Thr | p.A440T | A1A5B4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANO9 | SNV | Missense_Mutation | rs755167156 | c.2110G>A | p.Ala704Thr | p.A704T | A1A5B4 | protein_coding | deleterious(0.04) | benign(0.121) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ANO9 | SNV | Missense_Mutation | c.2343N>A | p.Asp781Glu | p.D781E | A1A5B4 | protein_coding | tolerated_low_confidence(1) | benign(0.007) | TCGA-D1-A17L-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |